Member Info for Saoirse12

Yes, good post Erincat> I've just picked up additional 296,000 in 3 trades. Have a great weekend all.

Excellent post Vares and the summary gives the reason why some of us are here and invested. Certain others like BD🤡🤡🤡 , just come across as a tad simple and never ever contribute anything whatsoever. Just the same old drivel and grabbing the odd sandwich money here and there 🤣. Thanks for the chart PD, you were bang on the money and the volume told the story !!

Summary of thesis :

Acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) are characterised by therapy resistance and relapse risk, reflecting immune dysfunction within the bone-marrow niche and the metabolic adaptability of malignant myeloid cells. This thesis establishes the biological and clinical relevance of the scavenger receptor Clever-1 (STAB1) in myeloid malignancies and evaluates therapeutic targeting with the anti–Clever-1 antibody bexmarilimab.

Clever-1 was consistently detected in malignant myeloid populations in AML cell lines and primary AML/MDS samples, including leukaemic blasts and CD34+ progenitors, with marked inter-patient heterogeneity. Expression was enriched in AML with monocytic differentiation (FAB M4–M5) compared with less differentiated AML and MDS, a pattern reproduced in independent transcriptomic cohorts.

Ex vivo Clever-1 blockade did not induce uniform cytotoxicity but promoted myeloid phenotypic modulation, most notably HLA-DR upregulation in antigen-presenting monocyte-like populations, and modified responsiveness to azacitidine and venetoclax in selected resistant settings. In a phase I/II clinical study with bexmarilimab treatment combined with azacitidine, the regimen demonstrated a manageable safety profile without dose-limiting toxicities and achieved sustained in vivo target engagement, evidenced by high receptor occupancy on circulating CD14+ monocytes and shifts away from an immunoregulatory phenotype. Clinical responses occurred across dose levels in high-risk MDS and relapsed/refractory AML, with activity associated with baseline immune composition rather than blast burden.

Mechanistically, we identify a previously unrecognised intracellular trafficking axis whereby AML cell–intrinsic Clever-1 translocates from the cell surface to mitochondrial compartments and regulates delivery of modified lipoprotein-derived cargo.

Disruption of this pathway reduced mitochondrial lipid incorporation, impaired complex IV assembly, and diminished respiratory capacity, particularly in models reliant on mitochondrial energy metabolism and under lipid-restricted conditions. Collectively, this PhD thesis establishes Clever-1 as a context-dependent immunometabolic regulator in malignant myeloid cells and justifies continued clinical development of Clever-1–targeted therapy in myeloid malignancies

In tandem......................🤣🤦‍♂️🤡 more cerebral contributors you will struggle to find !!

Looking forward to the deal announcement, suddenly......................

Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028*. This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and selectively invest in earlier-stage pipeline opportunities.

With the progress already underway, the Board believes 2026 will be a year of delivery, momentum, and success for ImmuPharma and its shareholders.

We look forward to updating you further on our progress.

This is the message I received from Juho directly a few weeks back when I raised concerns about the way this had been handled, expressing my disappointment. I believe we will be sitting comfortably again before to long.

This is the reply which I like a lot :

Hi XXXX,

Thank you for your email. We all were very surprised about the stock price reaction. The reaction likely reflects the problem of biotechs raising capital in Europe. We are highly confident in our capabilities and most importantly Bex itself is impaired and looking great from a clinical development perspective. Hence, we believe the future is bright, so let’s just clear this financial overhang and move on. But as I can see the end goal, I believe we will be rewarded handsomely, alleviating these pains we are currently feeling with respect to current share price.

Keep calm and think 'Clever'.

Best regards,

Juho

Currently SP sits at 52.5p, patience and will recover slowly over next 8 months and should be over a £1 by Christmas.

Will rise rapidly towards £1 over next few months !! Very strong and very undervalued due to Juho's shenanigans

Correct, this will re-rate very quickly when the dust settles and the those underwiriting the 40 million will clean up !!

I have loaded up in anticipation.

I feel your pain OTM : you keep losing £17,000 per penny drop, that has gotta hurt, oh well, bring on the 5's !!!

Yes Clintek, I watched too and it was very positive. Lots of upside to this and appears the science for BEX is gold standard from trials to date. Also excellent that the FDA are being extremely supportive in discussing design of PII/III, and excellent news that the various hospital/investigator trials are being initiated soon at the behest of various IIT's.

All very 'CLEVER' !!!!

Just bought in today after reading about Bex and discussing via email to company about recent drop in SP due to fund raise. What surprises me is that on the day the share price collapsed 65%, the volume of shares traded was under 1% of the total shares which wiped off over £120 million. This will rise very quickly on any small volume of shares purchased. Think this is in bargain basement territory and now happy to wait for the return to the £2 range.

This is the reply which I like a lot :

Hi XXXX,

Thank you for your email. We all were very surprised about the stock price reaction. The reaction likely reflects the problem of biotechs raising capital in Europe. We are highly confident in our capabilities and most importantly Bex itself is impaired and looking great from a clinical development perspective. Hence, we believe the future is bright, so let’s just clear this financial overhang and move on. But as I can see the end goal, I believe we will be rewarded handsomely, alleviating these pains we are currently feeling with respect to current share price.

Keep calm and think 'Clever'.

Best regards,

The phrase IMM would use are 'partnership discussions are ongoing'. And, yes, still valid.

Good post Syn: Bodes well for future, big boys know what they are doing !! I think accumulation has been going on for past few months very discreetly without affecting a sharp rise in SP, think the shares of relatively small shareholders are being taken little by little.............

Offering 8.1 to sell.......................Mmmmmmmmmmm

As u say, patience !!

Great post Hamil : I too do not want pointless updates from the company. When the 1st deal is ready, the news should be released. Ignore the pointless drivel from the chosen ones.

Patience and share collection. Tim and the team have done a brilliant job and we LTH's will reap the rewards in 2026. Fully funded and when announced, prepare for the 400 messages/day on here !!!

Very quietly over past couple of weeks, somebody is nibbling away building a little nest egg in IMM, under the radar, adagio, adagio

Just took another 150,000 @ 8.059 and 85,111 @ 8.1

Q1 and all on target for the DEAL announcement. Have a funny feeling we will be very happy !!!

Well done Seb et al 👏👏👏👏

Expect 15p to go before Friday evening on no release of news. It's folks buying back in as news will be coming in next 6 weeks and FOMO, the ones who sold on Nov 24 2025.

Massive re-rate coming.

Chill and enjoy the nonsense. Well done all LTH's, our time to reap the rewards of those dark days is coming to fruition.

MSUK.Int.................... Great Analysis as usual, all those posts and yet............🤣🤡🤡🤡🤦‍♂️

Very easy ,charts is the language of the stock ,there is a word in each candle ,few candles tells a sentence ,the idea is to get % in your bias ,charts indicates what probabilities % are like ly to be in your favour ,what your trying to do is minmise risk so by default your increse your reward ..everyone who is in the market should get familiar with reading a chart its the best thing you will ever do ,back in mid nov 25 i stated price has broken below 50ema (c 9.50) big sign ,all the haters came out ,price is now c 35% lower ...

Accumulation with a hint of subtleness, 3 months ago almost when delay was 1st announced on 24 Feb 25, SP dropped instantly from 9.7p to 6.7p, the reverse will happen now and I suspect 10p very quickly as new base before the news arrives and then.......................

?????????????????????????

Morning Halfbutt,

I don't think Stout/Syn were asking you to believe them, just posting like you do most days. If I was these posters, I think I would not have posted within a nanosecond, but rather, probably have been filling my boots with as many shares I could buy at the lowest prices before the SP started to rise on any potential news arriving. Maybe, just maybe, these posters have already adjusted their risk appetite and portfolio appropriately to their needs. That's what I have done.

As for LLOLolly, I sincerely hope you have made a fortune with your investment strategy across your investment portfolio, however suspect you are bitter that you have 'missed the boat' on a number of occasions. You have never contributed a single iota of knowledge to any of the chat boards. From what I read, you were complaining about IMM when the share price was less than a penny. Who knew that nostalgia had a scent? And why did it always smell a little like regret?????

I agree with some other posters on this BB that believe TM has delivered exactly what he stated at the start of 2025. NO LIES, just an excellent year for shareholders and HAS been transformational from a scientific perspective too.

The discovery of a NEW mechanism of action and identification of Type M, a sub-type of auto-immune disorders, greatly expands the scope of P140 across a wide range of autoimmune diseases. This discovery significantly enhances the business case due to the potential for long-term increased revenues.

This combination makes P140 a unique and extremely valuable asset, particularly with the potential for 20 years of commercial exclusivity, and will add enormous traction to our current discussions with potential global partners of P140.

Dr Sébastien Goudreau CSO of ImmuPharma, "We are delighted that our innovative research methods have provided the internally generated (and externally validated) scientific data to support this new patent application on P140, proving that our research approach is highly effective in the extremely competitive landscape of pharmaceutical development.

Expecting a huge announcement in Q1 relating to pharma deal, substantial upfront payment to IMM and ongoing long term royalties.

Nobody knows exactly when. Patience is the key. But when the news drops.....................